Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome.
Gavriatopoulou M, Ntanasis-Stathopoulos I, Fotiou D, Migkou M, Eleutherakis-Papaiakovou E, Kanellias N, Roussou M, Dialoupi I, Malandrakis P, Theodorakakou F, Kastritis E, Terpos E, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: migkou m. Hemasphere. 2020 May 21;4(3):e381. doi: 10.1097/HS9.0000000000000381. eCollection 2020 Jun. Hemasphere. 2020. PMID: 32647800 Free PMC article. No abstract available.
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, Tassidou A, Xilouri I, Delibasi S, Psimenou E, Mellou S, Terpos E, Nanas J, Dimopoulos MA. Kastritis E, et al. Among authors: migkou m. Haematologica. 2007 Oct;92(10):1351-8. doi: 10.3324/haematol.11325. Haematologica. 2007. PMID: 18024372 Free article. Clinical Trial.
Treatment of light chain deposition disease with bortezomib and dexamethasone.
Kastritis E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadjikonstantinou V, Dimopoulos MA. Kastritis E, et al. Among authors: migkou m. Haematologica. 2009 Feb;94(2):300-2. doi: 10.3324/haematol.13548. Epub 2008 Dec 9. Haematologica. 2009. PMID: 19066331 Free PMC article. No abstract available.
Angiogenesis in Waldenström's macroglobulinemia.
Terpos E, Tasidou A, Kastritis E, Eleftherakis-Papaiakovou E, Gavriatopoulou M, Migkou M, Dimopoulos MA. Terpos E, et al. Among authors: migkou m. Clin Lymphoma Myeloma. 2009 Mar;9(1):46-9. doi: 10.3816/CLM.2009.n.011. Clin Lymphoma Myeloma. 2009. PMID: 19362971 Review.
Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA, Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Migkou M, Gavriatopoulou M, Tassidou A, Terpos E. Dimopoulos MA, et al. Among authors: migkou m. Clin Lymphoma Myeloma. 2009 Mar;9(1):59-61. doi: 10.3816/CLM.2009.n.015. Clin Lymphoma Myeloma. 2009. PMID: 19362975 Review.
Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M, Terpos E. Gavriatopoulou M, et al. Among authors: migkou m. Expert Opin Ther Targets. 2009 Jul;13(7):839-48. doi: 10.1517/14728220903025770. Expert Opin Ther Targets. 2009. PMID: 19530987 Review.
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E. Dimopoulos MA, et al. Among authors: migkou m. Clin Lymphoma Myeloma. 2009 Aug;9(4):302-6. doi: 10.3816/CLM.2009.n.059. Clin Lymphoma Myeloma. 2009. PMID: 19717380
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.
Terpos E, Dimopoulos MA, Shrivastava V, Leitzel K, Christoulas D, Migkou M, Gavriatopoulou M, Anargyrou K, Hamer P, Kastritis E, Carney W, Lipton A. Terpos E, et al. Among authors: migkou m. Leuk Res. 2010 Mar;34(3):399-402. doi: 10.1016/j.leukres.2009.08.035. Epub 2009 Sep 24. Leuk Res. 2010. PMID: 19781774
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, Matsouka C, Mparmparoussi D, Psimenou E, Grapsa I, Efstathiou E, Terpos E. Dimopoulos MA, et al. Among authors: migkou m. Eur J Haematol. 2010 Jul;85(1):1-5. doi: 10.1111/j.1600-0609.2010.01432.x. Epub 2010 Feb 20. Eur J Haematol. 2010. PMID: 20192988
115 results